HIV 感染者两剂次 SARS-CoV-2 信使 RNA 疫苗接种的安全性和抗体应答。
Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV.
机构信息
Department of Surgery.
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine.
出版信息
AIDS. 2021 Nov 15;35(14):2399-2401. doi: 10.1097/QAD.0000000000003017.
Abstract
This study of SARS-CoV-2 mRNA vaccination in 14 persons with HIV (PWH) demonstrated uniformly high anti-SARS-CoV-2 receptor binding domain (RBD) antibody titres after two doses, despite varied titres after a single dose. The majority of vaccine reactions were mild and no adverse events occurred.
摘要
这项研究纳入了 14 名 HIV 感染者（PWH），结果表明，在接种两剂 SARS-CoV-2 mRNA 疫苗后，所有受试者的抗 SARS-CoV-2 受体结合域（RBD）抗体滴度均较高，尽管单剂接种后的滴度存在差异。大多数疫苗反应为轻度，且未发生不良事件。
相似文献
1
Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV.
AIDS. 2021 Nov 15;35(14):2399-2401. doi: 10.1097/QAD.0000000000003017.
2
Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV.
AIDS. 2021 Sep 1;35(11):1872-1874. doi: 10.1097/QAD.0000000000002945.
3
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Lancet Microbe. 2022 Mar;3(3):e193-e202. doi: 10.1016/S2666-5247(21)00280-9. Epub 2022 Jan 24.
4
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
Lancet Infect Dis. 2022 May;22(5):636-648. doi: 10.1016/S1473-3099(21)00764-7. Epub 2022 Jan 25.
5
Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Lancet Healthy Longev. 2022 Mar;3(3):e166-e175. doi: 10.1016/S2666-7568(22)00012-5. Epub 2022 Feb 23.
6
Limited Humoral and Specific T-Cell Responses After SARS-CoV-2 Vaccination in PWH With Poor Immune Reconstitution.
J Infect Dis. 2022 Nov 28;226(11):1913-1923. doi: 10.1093/infdis/jiac406.
7
Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?
Infection. 2022 Dec;50(6):1573-1577. doi: 10.1007/s15010-022-01816-9. Epub 2022 Apr 7.
8
Impact on HIV-1 RNA Levels and Antibody Responses Following SARS-CoV-2 Vaccination in HIV-Infected Individuals.
Front Immunol. 2022 Feb 10;12:820126. doi: 10.3389/fimmu.2021.820126. eCollection 2021.
9
Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine.
Int J Infect Dis. 2022 May;118:116-118. doi: 10.1016/j.ijid.2022.02.036. Epub 2022 Feb 19.
10
Antibody response following the third and fourth SARS-CoV-2 vaccine dose in individuals with common variable immunodeficiency.
Front Immunol. 2022 Jul 28;13:934476. doi: 10.3389/fimmu.2022.934476. eCollection 2022.
引用本文的文献
1
Distinct immune responses in people living with HIV following SARS-CoV-2 recovery.
Commun Med (Lond). 2025 Apr 23;5(1):132. doi: 10.1038/s43856-025-00839-1.
2
Efficacy of COVID-19 Vaccination in People Living with HIV/AIDS in a Northern Brazil: Cross-Sectional Study.
Vaccines (Basel). 2025 Mar 7;13(3):283. doi: 10.3390/vaccines13030283.
3
Severe acute respiratory syndrome coronavirus-2 antibody prevalence in adults with HIV.
AIDS. 2025 Jul 15;39(9):1178-1184. doi: 10.1097/QAD.0000000000004180. Epub 2025 Mar 13.
4
Estimation of vaccine effectiveness against SARS-CoV-2-associated hospitalization using sentinel surveillance in South Africa.
Int J Epidemiol. 2024 Aug 14;53(5). doi: 10.1093/ije/dyae116.
5
COVID-19 Breakthrough Infections Among People With HIV: A Statewide Cohort Analysis.
J Acquir Immune Defic Syndr. 2024 Oct 1;97(2):107-116. doi: 10.1097/QAI.0000000000003475.
6
Serum SARS-CoV-2 antibodies in HIV-1-infected patients after inactivated vaccination and SARS-CoV-2 infection.
Heliyon. 2024 May 23;10(11):e31731. doi: 10.1016/j.heliyon.2024.e31731. eCollection 2024 Jun 15.
7
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
PLOS Glob Public Health. 2024 Apr 11;4(4):e0002703. doi: 10.1371/journal.pgph.0002703. eCollection 2024.
8
Effects of COVID-19 mRNA vaccination on HIV viremia and reservoir size.
AIDS. 2024 Jul 1;38(8):1120-1130. doi: 10.1097/QAD.0000000000003841. Epub 2024 Jan 22.
9
Effects of COVID-19 mRNA vaccination on HIV viremia and reservoir size.
medRxiv. 2023 Oct 9:2023.10.08.23296718. doi: 10.1101/2023.10.08.23296718.
10
The immune response to SARS-CoV-2 in people with HIV.
Cell Mol Immunol. 2024 Feb;21(2):184-196. doi: 10.1038/s41423-023-01087-w. Epub 2023 Oct 11.
本文引用的文献
1
In Search of the SARS-CoV-2 Protection Correlate: Head-to-Head Comparison of Two Quantitative S1 Assays in Pre-characterized Oligo-/Asymptomatic Patients.
Infect Dis Ther. 2021 Jun 16:1-14. doi: 10.1007/s40121-021-00475-x.
2
High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases.
Ann Rheum Dis. 2021 Oct;80(10):1351-1352. doi: 10.1136/annrheumdis-2021-220656. Epub 2021 May 24.
3
Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV.
AIDS. 2021 Sep 1;35(11):1872-1874. doi: 10.1097/QAD.0000000000002945.
4
Vaccination strategy and anti - SARS-CoV-2 S titers in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy).
Infect Agent Cancer. 2021 May 12;16(1):32. doi: 10.1186/s13027-021-00375-2.
5
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients.
JAMA. 2021 Jun 1;325(21):2204-2206. doi: 10.1001/jama.2021.7489.
6
Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients.
Ann Oncol. 2021 Aug;32(8):1051-1053. doi: 10.1016/j.annonc.2021.04.020. Epub 2021 Apr 29.
7
Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay.
J Clin Virol. 2021 Jun;139:104820. doi: 10.1016/j.jcv.2021.104820. Epub 2021 Apr 10.
8
Safety and Reactogenicity of 2 Doses of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients.
Transplantation. 2021 Oct 1;105(10):2170-2174. doi: 10.1097/TP.0000000000003780.
9
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.
Gut. 2021 May;70(5):865-875. doi: 10.1136/gutjnl-2021-324388. Epub 2021 Mar 22.
10
Antibodies against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in individuals with and without COVID-19 vaccination: A method comparison of two different commercially available serological assays from the same manufacturer.
Clin Chim Acta. 2021 Jul;518:9-16. doi: 10.1016/j.cca.2021.03.007. Epub 2021 Mar 17.
Zotero 插件